30th Sep 2013 06:24
LONDON (Alliance News) - Vectura Group Plc. (VEC.L) and Belgium-based biopharmaceutical company UCB said they have entered into a collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease. Financial terms of the deal were not disclosed.
The collaboration aims to leverage Vectura's expertise in the pharmaceutical and clinical/regulatory development of inhaled therapeutics with UCB's biologics and immunology assets.
It will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system.
The companies will jointly manage the program. While UCB will focus on bioprocess and preclinical development, Vectura will take responsibility for the pharmaceutical and clinical development of the dry powder product through to clinical proof-of-concept.
Copyright RTT News/dpa-AFX
Related Shares:
VEC.L